PubRank

Gemma Casadesus

Author PubWeight™ 73.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 2008 3.68
2 Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem 2007 1.85
3 Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 2011 1.57
4 LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 2012 1.56
5 Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 2004 1.49
6 Pet-1 is required across different stages of life to regulate serotonergic function. Nat Neurosci 2010 1.48
7 Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis 2009 1.42
8 Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2010 1.37
9 Oxidative stress signalling in Alzheimer's disease. Brain Res 2004 1.33
10 Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am J Clin Nutr 2005 1.32
11 Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun 2008 1.31
12 The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol 2011 1.27
13 Vascular oxidative stress in Alzheimer disease. J Neurol Sci 2007 1.25
14 Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 2006 1.19
15 Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int 2008 1.18
16 Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002 1.17
17 Klf15 orchestrates circadian nitrogen homeostasis. Cell Metab 2012 1.14
18 The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. Am J Pathol 2009 1.08
19 Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 2005 1.05
20 From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis 2008 1.04
21 The cell cycle in Alzheimer disease: a unique target for neuropharmacology. Mech Ageing Dev 2005 1.04
22 Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett 2009 1.02
23 A novel approach to the identification and quantitative elemental analysis of amyloid deposits--insights into the pathology of Alzheimer's disease. Biochem Biophys Res Commun 2009 1.02
24 Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci 2004 1.01
25 Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J Alzheimers Dis 2007 1.01
26 Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. J Neurochem 2013 1.00
27 Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic Res 2009 1.00
28 Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Mol Neurodegener 2008 1.00
29 Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother 2010 0.97
30 Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol Aging 2011 0.96
31 Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007 0.95
32 The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 2007 0.95
33 The role of metabotropic glutamate receptors in Alzheimer's disease. Acta Neurobiol Exp (Wars) 2004 0.94
34 Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease. Int J Biomed Sci 2010 0.94
35 A metabolic basis for Alzheimer disease. Neurochem Res 2003 0.94
36 Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis. Ann N Y Acad Sci 2005 0.92
37 Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice. Invest Ophthalmol Vis Sci 2009 0.91
38 Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence. Mech Ageing Dev 2007 0.91
39 Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits. J Neurochem 2009 0.90
40 Mitochondrial biology in Alzheimer's disease pathogenesis. J Neurochem 2010 0.90
41 All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother 2009 0.90
42 Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem 2005 0.89
43 Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome. J Neurochem 2012 0.89
44 Clinical benefit and preservation of flavonols in dark chocolate manufacturing. Nutr Rev 2008 0.89
45 Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain. J Biol Chem 2014 0.88
46 Walking toward a convergence in aging research. Front Neurosci 2009 0.88
47 Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. Int J Clin Exp Pathol 2008 0.87
48 Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease. Mol Neurodegener 2006 0.87
49 The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target. Curr Pharm Des 2006 0.86
50 Perspectives on the amyloid-beta cascade hypothesis. J Alzheimers Dis 2004 0.86
51 Autophagy in Alzheimer's disease. Expert Rev Neurother 2010 0.85
52 Frontiers in Alzheimer's disease therapeutics. Ther Adv Chronic Dis 2011 0.84
53 Gender differences in Alzheimer disease: the role of luteinizing hormone in disease pathogenesis. Alzheimer Dis Assoc Disord 2005 0.83
54 Lithium treatment decreases activities of tau kinases in a murine model of senescence. J Neuropathol Exp Neurol 2008 0.83
55 The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Res 2008 0.82
56 Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease. Curr Alzheimer Res 2013 0.81
57 The X-chromosome instability phenotype in Alzheimer's disease: a clinical sign of accelerating aging? Med Hypotheses 2009 0.80
58 Gonadotropins and Alzheimer's disease: the link between estrogen replacement therapy and neuroprotection. Acta Neurobiol Exp (Wars) 2004 0.79
59 Retinoids for treatment of Alzheimer's disease. Biofactors 2012 0.78
60 Estrogen-mediated effects on cognition and synaptic plasticity: what do estrogen receptor knockout models tell us? Biochim Biophys Acta 2010 0.78
61 Chronic Leptin Supplementation Ameliorates Pathology and Improves Cognitive Performance in a Transgenic Mouse Model of Alzheimer's Disease. J Alzheimers Dis 2009 0.78
62 Gonadotropins: a cohesive gender-based etiology of Alzheimer disease. Mol Cell Endocrinol 2006 0.78
63 Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J Neurochem 2014 0.77
64 Neuroendocrinology-based therapy for Alzheimer's disease. Biofactors 2012 0.77
65 Respiratory and behavioral dysfunction following loss of the GABAA receptor α4 subunit. Brain Behav 2013 0.76
66 Accumulation of intraneuronal amyloid-β is common in normal brain. Curr Alzheimer Res 2014 0.76
67 Cell cycle aberrations in Alzheimer's disease: a novel therapeutic opportunity. Expert Rev Neurother 2009 0.76
68 Special issue on estrogen actions in the brain. Biochim Biophys Acta 2010 0.76
69 Transection of CA3 does not affect memory performance in rats. Epilepsy Behav 2011 0.75
70 Correction: Individual Case Analysis of Postmortem Interval Time on Brain Tissue Preservation. PLoS One 2016 0.75
71 Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease. Am J Pathol 2009 0.75
72 Treatment advances in Alzheimer's disease based on the oxidative stress model. F1000 Med Rep 2009 0.75